ArticleFrontiers in pharmacology2025
Risk factor identification for delayed excretion in pediatric high-dose methotrexate therapy: a machine learning analysis of real-world data.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacogenomics and Epigenetic Regulation Transforming Pediatric Precision Therapeutics.Journal of personalized medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study was to identify risk factors associated with delayed methotrexate (MTX) excretion in pediatric patients receiving high-dose MTX (HDMTX) therapy based on real-world data, and to develop and evaluate a predictive model. Methods: Clinical data were retrospectively collected from 1,485 pediatric HDMTX chemotherapy cycles at the Children's Hospital affiliated with Nanjing Medical University between 2021 and 2023. Key predictive variables were identified by Least Absolute Shrinkage and Selection Operator (LASSO) regression, Random Forest (RF), and Support Vector Machine Recursive Feature Elimination (SVM-RFE), and then incorporated into predictive models for MTX delayed excretion using Logistic Regression (LR), Naive Bayes (NB), Support Vector Machine (SVM), and Extreme Gradient Boosting (XGBoost). Bootstrap was employed to internally validate these models and identify the best-performing one, and then SHapley Additive exPlanations (SHAP) values were utilized to provide both global and local interpretations. Results: Among the 1,485 pediatric HDMTX chemotherapy cycles, 26.1% were associated with delayed MTX excretion. Serum creatinine (Scr), total drug dose (Dose), alkaline phosphatase (ALP), creatine kinase (CK), blood urea nitrogen (Urea), gamma-glutamyl transferase (GGT), hemoglobin (HB), and height were identified as key predictors of delayed excretion. Internal validation showed that the XGBoost model performed best, with an accuracy of 0.780, an F1 score of 0.669, an area under the Receiver Operating Characteristic curve (AUROC) of 0.842, and a Brier score of 0.136. Decision Curve Analysis (DCA) also demonstrated favorable clinical utility. SHAP analysis revealed that Scr was the most important risk factor for delayed MTX excretion in the XGBoost model. This XGBoost model has been translated into a convenient tool to facilitate its utility in clinical settings. Conclusion: The XGBoost model demonstrated good predictive performance and clinical utility for delayed MTX excretion in pediatric patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.